These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19625075)

  • 1. Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients.
    Kuczka K; Baum K; Picard-Willems B; Harder S
    Thromb Res; 2009 Nov; 124(5):625-30. PubMed ID: 19625075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
    Marciniak CM; Kaplan J; Welty L; Chen D
    PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
    Bara L; Planes A; Samama MM
    Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
    PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.
    Mahé I; Aghassarian M; Drouet L; Bal Dit-Sollier C; Lacut K; Heilmann JJ; Mottier D; Bergmann JF
    Thromb Haemost; 2007 Apr; 97(4):581-6. PubMed ID: 17393021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide.
    Mousa SA; Johansen K
    Int Angiol; 2005 Mar; 24(1):40-2. PubMed ID: 15876997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
    Siguret V; Pautas E; Février M; Wipff C; Durand-Gasselin B; Laurent M; Andreux JP; d'Urso M; Gaussem P
    Thromb Haemost; 2000 Nov; 84(5):800-4. PubMed ID: 11127859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin.
    Planès A; Samama MM; Lensing AW; Büller HR; Barre J; Vochelle N; Beau B
    Thromb Haemost; 1999 Jan; 81(1):22-5. PubMed ID: 10348714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactivity of enoxaparin in critically ill patients with normal renal function.
    Gouya G; Palkovits S; Kapiotis S; Madl C; Locker G; Stella A; Wolzt M; Heinz G
    Br J Clin Pharmacol; 2012 Nov; 74(5):806-14. PubMed ID: 23227470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
    Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
    Jeske W; Fareed J
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
    Sarig G; Blumenfeld Z; Leiba R; Lanir N; Brenner B
    Thromb Haemost; 2005 Nov; 94(5):980-5. PubMed ID: 16363240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation.
    Lang A; Kienitz C; Wetzel P; Rollnik JD
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):470-5. PubMed ID: 20547551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.
    Depasse F; González de Suso MJ; Lagoutte I; Fontcuberta J; Borrell M; Samama MM
    Thromb Res; 2003 Jan; 109(2-3):109-17. PubMed ID: 12706639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
    Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
    Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.
    Michalis LK; Katsouras CS; Papamichael N; Adamides K; Naka KK; Goudevenos J; Sideris DA
    Am Heart J; 2003 Aug; 146(2):304-10. PubMed ID: 12891200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.